沙格列扎作为二甲双胍和生活方式干预附加治疗多囊卵巢综合征女性的疗效与安全性(SLIM-PCOS试验):随机开放标签平行组临床试验研究方案
SLIM-PCOS是一项研究者发起的随机、开放标签、平行组、优效性临床试验,计划纳入约140例PCOS患者,1:1随机接受沙格列扎(4 mg/日)联合二甲双胍(500 mg 每日两次)及生活方式干预,或仅二甲双胍联合生活方式干预,治疗24周,随访至36周。主要结局为24周时血清SHBG较基线的变化。
要点
- 沙格列扎联合二甲双胍及生活方式干预治疗PCOS,主要看24周SHBG变化。
- 计划随机约140例PCOS患者,1:1分组,开放标签设计。
- 治疗24周,随访至36周,同时评估代谢、雄激素、肝脂肪变及安全性。
核心结论
- SLIM-PCOS试验旨在评估沙格列扎作为二甲双胍和生活方式干预附加治疗PCOS的疗效与安全性。
- 该试验将为沙格列扎在PCOS中的潜在治疗应用提供证据。
研究设计与样本
- 研究者发起的随机、开放标签、平行组、优效性临床试验。
- 计划随机约140例PCOS患者,1:1分配至沙格列扎(4 mg每日)联合二甲双胍(500 mg每日两次)及生活方式干预组,或二甲双胍联合生活方式干预组。
- 治疗24周,治疗后随访至36周,按意向性治疗(ITT)原则分析,双侧P值<0.05为有统计学意义。
关键数值与推荐
- 主要结局为24周时血清性激素结合球蛋白(SHBG)较基线的变化,组间比较。
- 次要疗效结局包括临床指标(人体测量、多毛、月经周期)、代谢与性腺参数(血脂、胰岛素抵抗、卵巢激素与雄激素、代谢综合征)、经腹部扫描的肝脂肪变及生活质量。
- 安全性结局包括患者报告的不良事件、血液学与生化安全参数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Emerging concepts on the role of insulin resistance (IR) in the pathogenesis of polycystic ovary syndrome (PCOS) have driven a shift in the therapeutic approach towards interventions targeting IR. SarogLItazar as an add-on to Metformin in PolyCystic Ovary Syndrome (SLIM-PCOS) trial aims to test the efficacy and safety of saroglitazar, a dual peroxisome proliferator-activated receptor (PPAR α/γ) agonist belonging to "glitazar" class of drugs, on top of metformin and lifestyle intervention in PCOS. METHODS: SLIM-PCOS is an investigator-initiated, randomized, open label, parallel group, superiority, clinical trial. Around 140 PCOS patients will be randomized in 1:1 ratio to either of the two study groups: Group A: tablet saroglitazar (4 mg daily) + tablet metformin (500 mg twice daily) + lifestyle intervention; and Group B: tablet metformin + lifestyle intervention. Lifestyle intervention will comprise of dietary intervention and physical activity. Treatment will be given for 24 weeks and post-treatment follow up done at 36 weeks. The primary outcome is to compare the change in serum sex hormone binding globulin (SHBG) levels at 24 weeks from baseline between the two groups. Secondary efficacy outcomes include clinical (anthropometry, hirsutism, menstrual cycles); metabolic and gonadal parameters (lipid profile, IR, ovarian hormones and androgens, metabolic syndrome); hepatic steatosis on transabdominal scan and quality of life. Safety outcomes include patient reported adverse events, hematological and biochemical safety parameters. Data will be analysed as per intention to treat (ITT) principle using validated statistical software. Two-tailed P-value < 0.05 will be considered statistically significant. DISCUSSION: SLIM-PCOS trial will provide evidence on the potential therapeutic application of saroglitazar in PCOS. Based on the study outcomes and the drug's mechanism of action, future studies may be planned to investigate into the role of this novel glitazar in PCOS patients having diabetes, dyslipidemia, non-alcoholic fatty liver disease and other associated co-morbidities. TRIAL REGISTRATION: Prospectively registered with the Clinical Trials Registry of India (Trial ID: CTRI/2025/09/094653); registered September 12, 2025. https://ctri.nic.in/Clinicaltrials/rmaindet.php?trialid=142027&EncHid=25944.27666&modid=1&compid=19 .
引用
- Mittal N, Singhal S, Mittal R, et al. Efficacy and safety of SarogLItazar as an add-on medication to Metformin and lifestyle intervention in women with PolyCystic Ovary Syndrome (SLIM-PCOS trial): study protocol for a randomized, open-label, parallel group clinical trial. Trials. 2026. PMID: 42271514. doi:10.1186/s13063-026-09534-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。